Elimination of intravenous di-2-ethylhexyl phthalate exposure abrogates most neonatal hypertension in premature infants with bronchopulmonary dysplasia

Research output: Contribution to journalArticlepeer-review

Abstract

(1) Background: The incidence of hypertension in very low birthweight (VLBW) infants in a single neonatal intensive care unit (NICU) dropped markedly during a 2-year period when the IV fluid (IVF) in both the antenatal unit and the NICU temporarily changed to a di-2-ethylhexyl phthalate (DEHP)-free formulation. The objective of the current report is to document this observation and demonstrate the changes in incidence of hypertension were not associated with the variation in risk factors for hypertension; (2) Methods: The charts of all VLBW infants born in a single NICU during a 7-year span were reviewed. This time includes 32 months of baseline, 20 months of DEHP-free IVF, 20 months of IVF DEHP re-exposure, and two 4-month washout intervals. The group of interest was limited to VLBW infants with bronchopulmonary dysplasia (BPD). Chi-square analysis was used to compare incidence of hypertension among periods. Vermont Oxford NICU Registry data were examined for variation in maternal and neonatal risk factors for hypertension; Results: Incidence of hypertension in VLBW infants with BPD decreased from 7.7% (baseline) to 1.4% when IVF was DEHP-free, rising back to 10.1% when DEHP-containing IVF returned to use. Risk factors for neonatal hypertension were stable across the 3 study periods in the NICU’s group of VLBW infants; (3) Conclusions: Serendipitous removal of IVF containing DEHP resulted in near elimination of hypertension in one NICU—an effect entirely reversed after the same brand of DEHP-containing IVF returned to clinical use. These results suggest that DEHP exposure from IVF plays a major role in neonatal hypertension.

Original languageEnglish (US)
Article number75
JournalToxics
Volume9
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • Bronchopulmonary dysplasia
  • Di-2-ethylhexyl phthalate (DEHP)
  • Epigenetics
  • Hypertension
  • Phthalates
  • Prematurity

ASJC Scopus subject areas

  • Toxicology
  • Chemical Health and Safety
  • Health, Toxicology and Mutagenesis

Fingerprint

Dive into the research topics of 'Elimination of intravenous di-2-ethylhexyl phthalate exposure abrogates most neonatal hypertension in premature infants with bronchopulmonary dysplasia'. Together they form a unique fingerprint.

Cite this